{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:55:25Z","timestamp":1777960525859,"version":"3.51.4"},"reference-count":60,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The presence of severe hypoxic stress can drive tumor growth, angiogenesis, and metastatic\ncharacteristics via up-regulated hypoxia-inducible factor 1-alpha (HIF-1\u03b1). Hence, targeting HIF-1\u03b1 is\nconsidered a promising strategy, as increased HIF-1\u03b1 activity is a key factor in the aggressive phenotype of malignancies.\nIn this study, we aimed to investigate the anti-cancer effects of several flavonoids, both single and in\ncombination with PX-478, in breast cancer cell lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We tested the effects of luteolin and PX-478, both alone and in combination, on HIF-1\u03b1 level in\nbreast cancer cells under hypoxia using the cell viability assay. To determine the rationale for the cell growth\ninhibition induced by the luteolin+PX-478 combination, we conducted experiments to assess cell survival, apoptosis,\ncell cycle, invasion, and migration under both normoxic and hypoxic conditions. Furthermore, we evaluated\nthe effect of this combination on DNA damage response under hypoxic stress via Comet assay and immunofluorescence\nstaining.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our findings revealed that the luteolin+PX-478 combination significantly suppressed the growth of\nMDA-MB-231 cells. In addition, we assessed time-dependent expression of HIF1\u03b1 in MDA-MB-231 cells and\nobserved that the combination of luteolin and PX-478 down-regulated the HIF-1\u03b1 level. Finally, we found that\nthe luteolin+PX-478 combination induced apoptosis and G2 cell cycle arrest and enhanced DNA damage response.\nThis combination also sensitized breast cancer cells to ionizing radiation in hypoxic stress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The findings suggested that targeting HIF-1\u03b1 with a combination of luteolin and PX-478 may provide\na synergistic approach to suppressing tumor growth and enhancing therapeutic response under hypoxic\nconditions. The observed effects on apoptosis, cell cycle arrest, and DNA damage response indicated that this\ncombination could be a promising strategy for overcoming hypoxia-induced resistance in breast cancer therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Collectively, our results suggested the combination of luteolin and PX-478 to enhance the anticancer\neffects of PX-478 in breast carcinoma cells by impeding the cell growth and inducing DNA damage response\nunder hypoxia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0118715206384227250901064037","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:03:56Z","timestamp":1757311436000},"page":"105-117","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Luteolin Enhances Anticancer Effects of PX-478 during Hypoxic Response in Metastatic Breast Cancer Cells"],"prefix":"10.2174","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6464-4353","authenticated-orcid":true,"given":"Muzaffer","family":"Dukel","sequence":"first","affiliation":[{"name":"Molecular Biology and Genetics Department, Faculty of Arts and Science, Burdur Mehmet Akif Ersoy University, Burdur, 15100,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3522-7531","authenticated-orcid":true,"given":"Fatema","family":"Zarzour","sequence":"additional","affiliation":[{"name":"Molecular Biology and Genetics Department, Faculty of Arts and Science, Burdur Mehmet Akif Ersoy University, Burdur, 15100,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"Bray F.","year":"2018","unstructured":"Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2018,68(6),394-424","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/S0140-6736(07)60781-8","volume":"369","author":"Eccles S.A.","year":"2007","unstructured":"Eccles S.A.; Welch D.R.; Metastasis: Recent discoveries and novel treatment strategies. Lancet  2007,369(9574),1742-1757","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/BD-2007-26105","volume":"26","author":"Chaudary N.","year":"2007","unstructured":"Chaudary N.; Hill R.P.; Hypoxia and metastasis in breast cancer. Breast Dis  2007,26(1),55-64","journal-title":"Breast Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/0360-3016(90)90018-F","volume":"19","author":"Kallinowski F.","year":"1990","unstructured":"Kallinowski F.; Zander R.; Hoeckel M.; Vaupel P.; Tumor tissue oxygenation as evaluated by computerized-po2-histography. Int J Radiat Oncol Biol Phys  1990,19(4),953-961","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/0-387-26206-7_44","volume":"566","author":"Vaupel P.","year":"2005","unstructured":"Vaupel P.; Mayer A.; Briest S.; H\u00f6ckel M.; Hypoxia in breast cancer: Role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. Adv Exp Med Biol  2005,566,333-342","journal-title":"Adv Exp Med Biol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1023\/A:1005921513083","volume":"48","author":"Hohenberger P.","year":"1998","unstructured":"Hohenberger P.; Felgner C.; Haensch W.; Schlag P.M.; Tumor oxygenation correlates with molecular growth determinants in breast cancer. Breast Cancer Res Treat  1998,48(2),97-106","journal-title":"Breast Cancer Res Treat"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1073\/pnas.1214019109","volume":"109","author":"Schito L.","year":"2012","unstructured":"Schito L.; Rey S.; Tafani M.; Zhang H.; Wong C.C.; Russo A.; Russo M.A.; Semenza G.L.; Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci USA  2012,109(40),2707-2716","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.2147\/IJN.S140462","volume":"13","author":"Graham K.","year":"2018","unstructured":"Graham K.; Unger E.; Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine  2018,13,6049-6058","journal-title":"Int J Nanomedicine"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10409238.2013.838205","volume":"49","author":"Dengler V.L.","year":"2014","unstructured":"Dengler V.L.; Galbraith M.D.; Espinosa J.M.; Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol  2014,49(1),1-15","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1074\/jbc.270.3.1230","volume":"270","author":"Wang G.L.","year":"1995","unstructured":"Wang G.L.; Semenza G.L.; Purification and characterization of hypoxia-inducible factor 1. J Biol Chem  1995,270(3),1230-1237","journal-title":"J Biol Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/med.21477","volume":"38","author":"Bhattarai D.","year":"2018","unstructured":"Bhattarai D.; Xu X.; Lee K.; Hypoxia\u2010inducible factor\u20101 (HIF\u20101) inhibitors from the last decade (2007 to 2016): A \u201cstructure\u2013activity relationship\u201d perspective. Med Res Rev  2018,38(4),1404-1442","journal-title":"Med Res Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/s12885-021-08186-9","volume":"21","author":"Parczyk J.","year":"2021","unstructured":"Parczyk J.; Ruhnau J.; Pelz C.; Schilling M.; Wu H.; Piaskowski N.N.; Eickholt B.; K\u00fchn H.; Danker K.; Klein A.; Dichloroacetate and PX-478 exhibit strong synergistic effects in a various number of cancer cell lines. BMC Cancer  2021,21(1),481","journal-title":"BMC Cancer"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/ijc.23807","volume":"123","author":"Palayoor S.T.","year":"2008","unstructured":"Palayoor S.T.; Mitchell J.B.; Cerna D.; DeGraff W.; John-Aryankalayil M.; Coleman C.N.; PX\u2010478, an inhibitor of hypoxia\u2010inducible factor\u20101\u03b1, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer  2008,123(10),2430-2437","journal-title":"Int J Cancer"},{"key":"ref=14","first-page":"1198","volume":"7","author":"Zhu Y.","year":"2017","unstructured":"Zhu Y.; Zang Y.; Zhao F.; Li Z.; Zhang J.; Fang L.; Li M.; Xing L.; Xu Z.; Yu J.; Inhibition of HIF-1\u03b1 by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo. Am J Cancer Res  2017,7(5),1198-1212","journal-title":"Am J Cancer Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/nu12020457","volume":"12","author":"Kopustinskiene D.M.","year":"2020","unstructured":"Kopustinskiene D.M.; Jakstas V.; Savickas A.; Bernatoniene J.; Flavonoids as anticancer agents. Nutrients  2020,12(2),457","journal-title":"Nutrients"},{"key":"ref=16","first-page":"2916","volume":"57","author":"Fotsis T.","year":"1997","unstructured":"Fotsis T.; Pepper M.S.; Aktas E.; Breit S.; Rasku S.; Adlercreutz H.; W\u00e4h\u00e4l\u00e4 K.; Montesano R.; Schweigerer L.; Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res  1997,57(14),2916-2921","journal-title":"Cancer Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/cancers11010028","volume":"11","author":"Abotaleb M.","year":"2018","unstructured":"Abotaleb M.; Samuel S.; Varghese E.; Varghese S.; Kubatka P.; Liskova A.; B\u00fcsselberg D.; Flavonoids in cancer and apoptosis. Cancers  2018,11(1),28","journal-title":"Cancers"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.procbio.2020.10.002","volume":"101","author":"D\u00fckel M.","year":"2021","unstructured":"D\u00fckel M.; Tavsan Z.; Kayali H.A.; Flavonoids regulate cell death-related cellular signaling via ROS in human colon cancer cells. Process Biochem  2021,101,11-25","journal-title":"Process Biochem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.3390\/cancers12061498","volume":"12","author":"Liskova A.","year":"2020","unstructured":"Liskova A.; Koklesova L.; Samec M.; Smejkal K.; Samuel S.M.; Varghese E.; Abotaleb M.; Biringer K.; Kudela E.; Danko J.; Shakibaei M.; Kwon T.K.; B\u00fcsselberg D.; Kubatka P.; Flavonoids in cancer metastasis. Cancers  2020,12(6),1498","journal-title":"Cancers"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2174\/138945006776055004","volume":"7","author":"Singh R.","year":"2006","unstructured":"Singh R.; Agarwal R.; Natural flavonoids targeting deregulated cell cycle progression in cancer cells. Curr Drug Targets  2006,7(3),345-354","journal-title":"Curr Drug Targets"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jnutbio.2005.05.009","volume":"17","author":"Gao K.","year":"2006","unstructured":"Gao K.; Henning S.; Niu Y.; Youssefian A.; Seeram N.; Xu A.; Heber D.; The citrus flavonoid naringenin stimulates DNA repair in prostate cancer cells. J Nutr Biochem  2006,17(2),89-95","journal-title":"J Nutr Biochem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.fitote.2011.01.018","volume":"82","author":"Proch\u00e1zkov\u00e1 D.","year":"2011","unstructured":"Proch\u00e1zkov\u00e1 D.; Bou\u0161ov\u00e1 I.; Wilhelmov\u00e1 N.; Antioxidant and prooxidant properties of flavonoids. Fitoterapia  2011,82(4),513-523","journal-title":"Fitoterapia"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/cancers13010130","volume":"13","author":"Samec M.","year":"2021","unstructured":"Samec M.; Liskova A.; Koklesova L.; Mersakova S.; Strnadel J.; Kajo K.; Pec M.; Zhai K.; Smejkal K.; Mirzaei S.; Hushmandi K.; Ashrafizadeh M.; Saso L.; Brockmueller A.; Shakibaei M.; B\u00fcsselberg D.; Kubatka P.; Flavonoids targeting HIF-1: Implications on cancer metabolism. Cancers  2021,13(1),130","journal-title":"Cancers"},{"key":"ref=24","first-page":"403","author":"G\u00fcrler S.B.","year":"2020","unstructured":"G\u00fcrler S.B.; Kiraz Y.; Baran Y.;  Chapter 21 - Flavonoids in cancer therapy: Current and future trendsBiodiversity and Biomedicine  2020,403-440","journal-title":"Chapter 21 - Flavonoids in cancer therapy: Current and future trendsBiodiversity and Biomedicine"},{"key":"ref=25","first-page":"1517","volume":"9","author":"Kikuchi H.","year":"2019","unstructured":"Kikuchi H.; Yuan B.; Hu X.; Okazaki M.; Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents. Am J Cancer Res  2019,9(8),1517-1535","journal-title":"Am J Cancer Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"Chou T.C.","year":"2010","unstructured":"Chou T.C.; Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res  2010,70(2),440-446","journal-title":"Cancer Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13273-022-00317-y","volume":"19","author":"Dukel M.","year":"2023","unstructured":"Dukel M.; Combination of naringenin and epicatechin sensitizes colon carcinoma cells to anoikis via regulation of the epithelial\u2013mesenchymal transition (EMT). Mol Cell Toxicol  2023,19(1),187-203","journal-title":"Mol Cell Toxicol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"Livak K.J.","year":"2001","unstructured":"Livak K.J.; Schmittgen T.D.; Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method Methods  2001,25(4),402-408","journal-title":"Method Methods"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/09553002.2022.2110326","volume":"99","author":"Dukel M.","year":"2023","unstructured":"Dukel M.; Fiskin K.; Combination of PAKs inhibitors IPA-3 and PF-3758309 effectively suppresses colon carcinoma cell growth by perturbing DNA damage response. Int J Radiat Biol  2023,99(2),340-354","journal-title":"Int J Radiat Biol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"7732","DOI":"10.3390\/ijms23147732","volume":"23","author":"Park M.Y.","year":"2022","unstructured":"Park M.Y.; Kim Y.; Ha S.E.; Kim H.H.; Bhosale P.B.; Abusaliya A.; Jeong S.H.; Kim G.S.; Function and application of flavonoids in the breast cancer. Int J Mol Sci  2022,23(14),7732","journal-title":"Int J Mol Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ph12010011","volume":"12","author":"Salehi B.","year":"2019","unstructured":"Salehi B.; Fokou P.V.T.; Sharifi-Rad M.; Zucca P.; Pezzani R.; Martins N.; Sharifi-Rad J.; The therapeutic potential of naringenin: A review of clinical trials. Pharmaceuticals  2019,12(1),11","journal-title":"Pharmaceuticals"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.7555\/JBR.33.20180126","volume":"33","author":"Vetrivel P.","year":"2019","unstructured":"Vetrivel P.; Kim S.M.; Saralamma V.V.G.; Ha S.E.; Kim E.H.; Min T.S.; Kim G.S.; Function of flavonoids on different types of programmed cell death and its mechanism: A review. J Biomed Res  2019,33(6),363","journal-title":"J Biomed Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"21541","DOI":"10.1074\/jbc.M116.730960","volume":"291","author":"D\u00fckel M.","year":"2016","unstructured":"D\u00fckel M.; Streitfeld W.S.; Tang T.C.C.; Backman L.R.F.; Ai L.; May W.S.; Brown K.D.; The breast cancer tumor suppressor TRIM29 is expressed via ATM-dependent signaling in response to hypoxia. J Biol Chem  2016,291(41),21541-21552","journal-title":"J Biol Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"Jing X.","year":"2019","unstructured":"Jing X.; Yang F.; Shao C.; Wei K.; Xie M.; Shen H.; Shu Y.; Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer  2019,18(1),157","journal-title":"Mol Cancer"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.canlet.2020.11.045","volume":"502","author":"McAleese C.E.","year":"2021","unstructured":"McAleese C.E.; Choudhury C.; Butcher N.J.; Minchin R.F.; Hypoxia-mediated drug resistance in breast cancers. Cancer Lett  2021,502,189-199","journal-title":"Cancer Lett"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"964934","DOI":"10.3389\/fonc.2022.964934","volume":"12","author":"Yong L.","year":"2022","unstructured":"Yong L.; Tang S.; Yu H.; Zhang H.; Zhang Y.; Wan Y.; Cai F.; The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer. Front Oncol  2022,12,964934","journal-title":"Front Oncol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"115235","DOI":"10.1016\/j.bmc.2019.115235","volume":"28","author":"Tang W.","year":"2020","unstructured":"Tang W.; Zhao G.; Small molecules targeting HIF-1\u03b1 pathway for cancer therapy in recent years. Bioorg Med Chem  2020,28(2),115235","journal-title":"Bioorg Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11426-010-4187-5","volume":"54","author":"Mooring S.R.","year":"2011","unstructured":"Mooring S.R.; Wang B.; HIF-1 inhibitors as anti-cancer therapy. Sci China Chem  2011,54(1),24-30","journal-title":"Sci China Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/nbm.977","volume":"18","author":"Jordan B.F.","year":"2005","unstructured":"Jordan B.F.; Black K.; Robey I.F.; Runquist M.; Powis G.; Gillies R.J.; Metabolite changes in HT-29 xenograft tumors following HIF-1\u03b1 inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed  2005,18(7),430-439","journal-title":"NMR Biomed"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/nbm.1632","volume":"24","author":"Avni R.","year":"2011","unstructured":"Avni R.; Cohen B.; Neeman M.; Hypoxic stress and cancer: Imaging the axis of evil in tumor metastasis. NMR Biomed  2011,24(6),569-581","journal-title":"NMR Biomed"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1002\/jcb.25972","volume":"118","author":"Carcereri de Prati A.","year":"2017","unstructured":"Carcereri de Prati A.; Butturini E.; Rigo A.; Oppici E.; Rossin M.; Boriero D.; Mariotto S.; Metastatic breast cancer cells enter into dormant state and express cancer stem cells phenotype under chronic hypoxia. J Cell Biochem  2017,118(10),3237-3248","journal-title":"J Cell Biochem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijrobp.2011.04.027","volume":"81","author":"Dai Y.","year":"2011","unstructured":"Dai Y.; Bae K.; Siemann D.W.; Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int J Radiat Oncol Biol Phys  2011,81,521-528","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1242\/dev.139071","volume":"143","author":"Campbell K.","year":"2016","unstructured":"Campbell K.; Casanova J.; A common framework for EMT and collective cell migration. Development  2016,143(23),4291-4300","journal-title":"Development"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10555-008-9169-0","volume":"28","author":"Yilmaz M.","year":"2009","unstructured":"Yilmaz M.; Christofori G.; EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev  2009,28(1-2),15-33","journal-title":"Cancer Metastasis Rev"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/bjc.2012.265","volume":"107","author":"Pires I.M.","year":"2012","unstructured":"Pires I.M.; Olcina M.M.; Anbalagan S.; Pollard J.R.; Reaper P.M.; Charlton P.A.; McKenna W.G.; Hammond E.M.; Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br J Cancer  2012,107(2),291-299","journal-title":"Br J Cancer"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"Siegel R.L.","year":"2023","unstructured":"Siegel R.L.; Miller K.D.; Wagle N.S.; Jemal A.; Cancer statistics, 2023. CA Cancer J Clin  2023,73(1),17-48","journal-title":"CA Cancer J Clin"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/HP.S93413","volume":"3","author":"Muz B.","year":"2015","unstructured":"Muz B.; de la Puente P.; Azab F.; Kareem Azab A.; The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia  2015,3,83-92","journal-title":"Hypoxia"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.3390\/ijms22115703","volume":"22","author":"Infantino V.","year":"2021","unstructured":"Infantino V.; Santarsiero A.; Convertini P.; Todisco S.; Iacobazzi V.; Cancer cell metabolism in hypoxia: Role of HIF-1 as key regulator and therapeutic target. Int J Mol Sci  2021,22(11),5703","journal-title":"Int J Mol Sci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"145796","DOI":"10.1016\/j.gene.2021.145796","volume":"798","author":"Rashid M.","year":"2021","unstructured":"Rashid M.; Zadeh L.R.; Baradaran B.; Molavi O.; Ghesmati Z.; Sabzichi M.; Ramezani F.; Up-down regulation of HIF-1\u03b1 in cancer progression. Gene  2021,798,145796","journal-title":"Gene"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.3390\/cancers14246054","volume":"14","author":"Bui B.P.","year":"2022","unstructured":"Bui B.P.; Nguyen P.L.; Lee K.; Cho J.; Hypoxia-inducible factor-1: A novel therapeutic target for the management of cancer, drug resistance, and cancer-related pain. Cancers  2022,14(24),6054","journal-title":"Cancers"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/jco.2010.28.15_suppl.3076","volume":"28","author":"Tibes R.","year":"2024","unstructured":"Tibes R.; Falchook G.S.; Von Hoff D.D.; Weiss G.J.; Iyengar T.; Kurzrock R.; Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1\u03b1. J Clin Oncol  (Suppl.)2024,28(15),3076","journal-title":"J Clin Oncol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s11101-019-09628-w","volume":"19","author":"Zhang Y.","year":"2020","unstructured":"Zhang Y.; Li H.; Zhang J.; Zhao C.; Lu S.; Qiao J.; Han M.; The combinatory effects of natural products and chemotherapy drugs and their mechanisms in breast cancer treatment. Phytochem Rev  2020,19(5),1179-1197","journal-title":"Phytochem Rev"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3892\/or.2012.2158","volume":"29","author":"Jeon Y.W.","year":"2013","unstructured":"Jeon Y.W.; Suh Y.J.; Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells. Oncol Rep  2013,29(2),819-825","journal-title":"Oncol Rep"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cbi.2014.02.002","volume":"213","author":"Yang M.Y.","year":"2014","unstructured":"Yang M.Y.; Wang C.J.; Chen N.F.; Ho W.H.; Lu F.J.; Tseng T.H.; Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3. Chem Biol Interact  2014,213,60-68","journal-title":"Chem Biol Interact"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.bbrc.2020.07.049","volume":"531","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Liu Q.; Huang L.; Yang F.; Liu A.; Zhang J.; Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a\/NQO1 pathway. Biochem Biophys Res Commun  2020,531(3),364-371","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.18632\/oncotarget.2948","volume":"6","author":"Zhao T.","year":"2015","unstructured":"Zhao T.; Ren H.; Jia L.; Chen J.; Xin W.; Yan F.; Li J.; Wang X.; Gao S.; Qian D.; Huang C.; Hao J.; Inhibition of HIF-1\u03b1 by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget  2015,6(4),2250-2262","journal-title":"Oncotarget"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2020-142154","volume":"136","author":"Muz B.","year":"2020","unstructured":"Muz B.; Wasden K.; Alhallak K.; Jeske A.; Azab F.; Sun J.; King J.; Kohnen D.R.; Vij R.; Azab A.K.; Inhibition of HIF-1a By PX-478 normalizes blood vessels, improves drug delivery and suppresses progression and dissemination in multiple myeloma. Blood  (Suppl. 1)2020,136,3","journal-title":"Blood"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1357801","DOI":"10.3389\/fonc.2024.1357801","volume":"14","author":"Panahi Meymandi A.R.","year":"2024","unstructured":"Panahi Meymandi A.R.; Akbari B.; Soltantoyeh T.; Shahosseini Z.; Hosseini M.; Hadjati J.; Mirzaei H.R.; PX-478, an HIF-1\u03b1 inhibitor, impairs mesoCAR T cell antitumor function in cervical cancer. Front Oncol  2024,14,1357801","journal-title":"Front Oncol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.2147\/OTT.S158206","volume":"11","author":"Xia Y.","year":"2018","unstructured":"Xia Y.; Jiang L.; Zhong T.; The role of HIF-1\u03b1 in chemo-\/radioresistant tumors. OncoTargets Ther  2018,11,3003-3011","journal-title":"OncoTargets Ther"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.canlet.2016.05.016","volume":"378","author":"Lang M.","year":"2016","unstructured":"Lang M.; Wang X.; Wang H.; Dong J.; Lan C.; Hao J.; Huang C.; Li X.; Yu M.; Yang Y.; Yang S.; Ren H.; Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma. Cancer Lett  2016,378(2),87-96","journal-title":"Cancer Lett"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715206384227250901064037","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/244992\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715206384227250901064037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:24:24Z","timestamp":1770791064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/244992\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0118715206384227250901064037","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}